Risk assessment in the European management of veterinary drug residues is done based on the EU Directives. The European Medicines Agency EMA lists the different scientific risks assessments that are carried out. Toxicology assessments are carried out. As of 2015 studies evaluating the safety concerns of veterinary drug residue in human food consumption have been released. The acute reference dose ARfD approach has been used here -Reference Number for this Draft VICH/699251/2010 (EMA, 2016; CVMP-VICH Safety Working Group, 2004). In 2014, the genotoxicity testing was done and guidelines were adopted accordingly. The second form of assessment that is carried out is the antimicrobials assessment. The use of antimicrobials has led to a general increase in the antimicrobial resistance. These risks assessments are conducted on a yearly basis again. The assessments have been published with a latest publish date of 17 July 2015 -Reference Number EMA/CVMP/AWP/37203/2015 (EMA, 2016). Similarly, there are risks assessments done with respect to user safety, environmental risk assessment and residual withdrawal period. Maximum residual limits MRLs establishment is also reviewed every year.
The establishment of MRLs, the risks assessment being done every year and the assessments being considered for comments every year is done to ensure there are no vulnerabilities in the management plan (Verbeke et al, 2007; Kemper, 2008). Any form of Governance breach of specific products such as the Group A products are seen to be treated more critically as these are directly dangerous to the health of people. This form of classifications of products that might cause a high risk impact versus products that might have a lesser impact shows the European management is more geared towards impact based risks assessment.